CYTOR and prostate cancer: We found that LINC00152 was increased in most cancers including bladder, breast, gastric, head/neck, kidney, liver, thyroid, cervix, blood, uterus, and colon cancers (FRKM log2 value > 1.4) but not prostate cancer (FRKM log2 = 0.67) (Fig. 2D).